Project Grant HT94252411116
Award Date
9/30/24
Completion Date
9/29/26
Dollars Obligated
$3.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
This $584,828 federal Project Grant award, funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the "HEROIC PROSTATE CANCER PRECISION HEALTH (PCAPH) AFRICA1K: POWERING PRECISION HEALTH TO IMPROVE PROSTATE CANCER OUTCOMES IN AFRICA" initiative. The grant, awarded to the University of Nairobi, a prominent Kenyan research university, aims to conduct advanced biomedical research and capacity-building focused on improving...
This Project Grant award of $231,009.44 from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420) supports research at the University of Adelaide in Australia to understand heterogeneity and improve the precision of prostate cancer clinical outcomes. The 3-year project, which runs from September 1, 2023 to August 31, 2026, aims to advance scientific understanding and develop new treatments related to prostate cancer, a key health condition affecting...
The University of Pretoria was awarded a $738,775 Project Grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, titled "HEROIC PROSTATE CANCER PRECISION HEALTH (PCAPH) AFRICA1K: POWERING PRECISION HEALTH TO IMPROVE PROSTATE CANCER OUTCOMES IN AFRICA", will fund research focused on transforming healthcare for military service members and the broader public through innovative and impactful prostate cancer...
This federal Project Grant award of $1,839,317.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Illinois. The grant aims to evaluate the interrelated roles of environmental exposures and multi-omic factors on high-risk prostate cancer among men of African ancestry. Key components include: Establishing a translational study site at the University of Calabar Teaching Hospital in Nigeria to recruit 120...
This federal Project Grant award for $1,518,817.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is for research to characterize the role of 3'-UTR biology as a mechanism of therapy response in high-risk prostate cancer. The award was made to the Weill Medical College of Cornell University, a prestigious academic medical institution with extensive experience conducting biomedical research for federal agencies. The project aims to...
This federal Project Grant award of $1,235,845.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is funding research at the University of Illinois to leverage data science methods to deliver individualized treatment effects in metastatic hormone sensitive prostate cancer. The project, with a performance period from August 15, 2025 to August 14, 2028, aims to transform healthcare for military service members and the general public...
The Defense Health Agency awarded a $1,346,633 Project Grant to the George Washington University under the Military Medical Research and Development federal grant program (CFDA 12.420) to conduct research titled "A PRIMARY ROLE FOR THE CIRCULATORY MICROENVIRONMENT IN AFRICAN AMERICAN PROSTATE CANCER DISPARITIES?" from May 15, 2023 to May 14, 2026. As the prime awardee, George Washington University will investigate medical solutions for prostate cancer disparities affecting African...
The University of Adelaide in Australia was awarded a $1,005,845 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from September 2022 through September 2025 to exploit prostate cancer metabolic dependencies to develop new therapeutics and circulating prognostic and predictive biomarkers. The Military Medical Research and Development program supports basic, applied, and...
This $260,250 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will fund research by Health Research, Inc. on the role of the SLC45A3-ELK4 chimera as a molecular determinant of prostate cancer health disparity. The research, to be conducted from March 2025 to March 2027, aims to advance scientific understanding of the genetic and molecular mechanisms underlying disparities in prostate cancer outcomes. As a leading...
The federal Project Grant award in the amount of $499,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), funds research by the Institute of Cancer Research: Royal Cancer Hospital (The) to study the interplay of molecular and spatial architectures with clinical states in prostate cancer. The research project aims to make discoveries that defeat cancer through innovative biomedical research. As a subawardee, the Institute of...